Zobrazeno 1 - 10
of 10
pro vyhledávání: '"замісна гормональна терапія"'
Publikováno v:
Ukrainian Journal «Health of Woman»; No. 5(162) (2022): Ukrainian Journal Health of Woman; 17-21
Ukrainian Journal «Health of Woman»; № 5(162) (2022): Ukrainian Journal Health of Woman; 17-21
Український журнал "Здоров'я жінки"; № 5(162) (2022): Український журнал Здоров’я жінки; 17-21
Ukrainian Journal «Health of Woman»; № 5(162) (2022): Ukrainian Journal Health of Woman; 17-21
Український журнал "Здоров'я жінки"; № 5(162) (2022): Український журнал Здоров’я жінки; 17-21
Women of menopausal age make up 10% of the world's population, and the problem of pathological menopause remains relevant today. Estrogen deficiency is considered to be the cause of menopause, so the use of replacement therapy is a pathogenetically s
Publikováno v:
Ukrainian Journal «Health of Woman»; No. 4(161) (2022): Ukrainian Journal Health of Woman; 43-48
Ukrainian Journal «Health of Woman»; № 4(161) (2022): Ukrainian Journal Health of Woman; 43-48
Український журнал "Здоров'я жінки"; № 4(161) (2022): Український журнал Здоров’я жінки; 43-48
Ukrainian Journal «Health of Woman»; № 4(161) (2022): Ukrainian Journal Health of Woman; 43-48
Український журнал "Здоров'я жінки"; № 4(161) (2022): Український журнал Здоров’я жінки; 43-48
The problem of menopause has been relevant for many decades. A pathogenetically justified method of treatment, taking into account the change in the hormonal background of a woman, is hormone replacement therapy. Determination of immune markers of ce
Publikováno v:
Збірник наукових праць Асоціації акушерів-гінекологів України; № 2(50) (2022); 17-20
Scientific digest of association of obstetricians and gynecologists of Ukraine; No. 2(50) (2022); 17-20
СБОРНИК НАУЧНЫХ ТРУДОВ Ассоциации акушеров-гинекологов Украины; № 2(50) (2022); 17-20
Scientific digest of association of obstetricians and gynecologists of Ukraine; No. 2(50) (2022); 17-20
СБОРНИК НАУЧНЫХ ТРУДОВ Ассоциации акушеров-гинекологов Украины; № 2(50) (2022); 17-20
Premature ovarian failure (POF) –pathological condition characterized by amenorrhea, infertility, symptoms of hypoestrogyny on the background of increased levels of gonadotropins (in women under 40 years. To fill the deficit of sex hormones in the
Publikováno v:
Reproductive Endocrinology; № 50 (2019); 12-16
Репродуктивная эндокринология; № 50 (2019); 12-16
Репродуктивна ендокринологія; № 50 (2019); 12-16
Репродуктивная эндокринология; № 50 (2019); 12-16
Репродуктивна ендокринологія; № 50 (2019); 12-16
Premature ovarian insufficiency (POI) is a rare but very damaging lifestyle condition that occurs at 1–1.5 of women and means termination of menstrual function up to 40 years old. POI impact on women’s wellbeing includes lipid metabolism dysregul
Publikováno v:
Reproductive Endocrinology; № 49 (2019); 58-61
Репродуктивная эндокринология; № 49 (2019); 58-61
Репродуктивна ендокринологія; № 49 (2019); 58-61
Репродуктивная эндокринология; № 49 (2019); 58-61
Репродуктивна ендокринологія; № 49 (2019); 58-61
Premature ovarian failure (POF) is still a disease with an unknown etiology; questions of early diagnosis and treatment remain open. POF is associated with typical menopausal symptoms which develop before the age of 40 years.The authors’ study invo
Publikováno v:
Health of Man; № 2 (2019); 6-12
Здоровье мужчины; № 2 (2019); 6-12
Здоров'я чоловіка; № 2 (2019); 6-12
Здоровье мужчины; № 2 (2019); 6-12
Здоров'я чоловіка; № 2 (2019); 6-12
Hormone replacement therapy in hypogonadism of different genesis is an effective treatment with the possibility of reversibility of changes in hormonal levels. The earlier the signs of hypogonadism are verified, the more successful will be its correc
Publikováno v:
Reproductive Endocrinology; № 46 (2019); 72-81
Репродуктивная эндокринология; № 46 (2019); 72-81
Репродуктивна ендокринологія; № 46 (2019); 72-81
Репродуктивная эндокринология; № 46 (2019); 72-81
Репродуктивна ендокринологія; № 46 (2019); 72-81
Hormone replacement therapy is still a popular and most effective treatment for vasomotor symptoms and bone loss prevention in the postmenopause but it is not without risks. This has driven many climacteric women to seek for alternatives, chiefly nat
Publikováno v:
Репродуктивна ендокринологія; № 32 (2016); 87-98
Репродуктивная эндокринология; № 32 (2016); 87-98
Reproductive Endocrinology; № 32 (2016); 87-98
Репродуктивная эндокринология; № 32 (2016); 87-98
Reproductive Endocrinology; № 32 (2016); 87-98
The International Menopause Society (IMS) has produced these new 2016 recommendations on women’s midlife health and menopause hormone therapy to help guide health-care professionals in optimizing their management of women in the menopause transitio
Publikováno v:
Репродуктивна ендокринологія; № 17 (2014); 72-75
Репродуктивная эндокринология; № 17 (2014); 72-75
Reproductive Endocrinology; № 17 (2014); 72-75
Репродуктивная эндокринология; № 17 (2014); 72-75
Reproductive Endocrinology; № 17 (2014); 72-75
A study of using the drug Sagenit in women reproductive age with climacteric syndrome was done. We observed 50 patients aged 37–49 years with climacteric disorders mild to moderate severity. Treatment lasts for a one month. Effectiveness of the dru
Publikováno v:
Репродуктивна ендокринологія; № 9 (2013); 7-12
Репродуктивная эндокринология; № 9 (2013); 7-12
Reproductive Endocrinology; № 9 (2013); 7-12
Репродуктивная эндокринология; № 9 (2013); 7-12
Reproductive Endocrinology; № 9 (2013); 7-12
У статті представлено основні принципи Рекомендацій Міжнародного товариства менопаузи з використання замісної гормональної терапії (2